Home Newsfeeds Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.62) by 33.87 percent.

byBenzinga Newsdesk

March 8, 2023

1 minute read

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.62) by 33.87 percent.

Gray Television Posts Mixed Q3 Earnings: Will Q4 Revenue Come In Below Consensus?

By Lekha Gupta

November 8, 12:17 PM

Gray Television Inc (NYSE: GTN) reported third-quarter (Q3) FY23 sales fell 12% Y/Y to $803 million, beating the analyst

GTN

Wells Fargo Maintains Overweight on Angi, Lowers Price Target to $9

By Benzinga Newsdesk

August 11, 8:00 AM

Wells Fargo analyst Brian Fitzgerald maintains Angi (NASDAQ:ANGI) with a Overweight and lowers the price target from $11 to $9.

ANGI

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak’s Takeover Bid Valued Up To $7.75/Share

By Vandana Singh

April 17, 12:29 PM

Vanda Pharmaceuticals rebuffs unsolicited proposals from Future Pak LLC, citing undervaluation. Offers up to $7.75 per share. Board asserts resilient business with FDA-approved products. Future Pak urged to reconsider terms for fair shareholder value.

VNDA

Susquehanna Upgrades Silicon Motion Technology to Positive

By Benzinga Newsdesk

October 5, 6:20 AM

Susquehanna analyst Mehdi Hosseini upgrades Silicon Motion Technology (NASDAQ:SIMO) from Neutral to Positive.

SIMO

Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Related Posts

Gray Television Posts Mixed Q3 Earnings: Will Q4 Revenue Come In Below Consensus?

Wells Fargo Maintains Overweight on Angi, Lowers Price Target to $9

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak’s Takeover Bid Valued Up To $7.75/Share

Susquehanna Upgrades Silicon Motion Technology to Positive